Form D · Biotechnology
Coridea NC1, Inc.
New York, NY · CIK 0001508105
Offering snapshot reported Jun 7, 2012 · SEC filing
- Reported sold
- $5M Offering amount: $10M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 7, 2012 | Initial | $5,000,000 | No comparison | 3 | SEC filing |
| Oct 17, 2011 | Amendment | $3,000,000 | $2,000,000vs Dec 17, 2010 | 3 | SEC filing |
| Dec 17, 2010 | Initial | $1,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-179426
Source: Form D, filed Jun 7, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mitchell S. Bloom | Executive |
| Neil Exter | Director |
| Mark Gelfand | Executive |
| Howard R. Levin, M.D. | Director, Executive |
| Jonathan Wyler | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O G&L Consulting, Llc 134 W. 26th Street, Suite 1011
New York, NY, 10001
New York, NY, 10001